Research programme: anticancer monoclonal antibodies - MabVax/MSKCC

Drug Profile

Research programme: anticancer monoclonal antibodies - MabVax/MSKCC

Alternative Names: 1B7; 1B7/31F; HuMab-1B7; HuMab-31F9; HuMab-Tn; r5B1

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MabVax Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action GD2 ganglioside inhibitors; Tumour-associated carbohydrate antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Nov 2017 HuMab-Tn fully -human monoclonal antibodies is still in preclinical studies for Cancer in USA (Mabvax Therapeutics pipeline, November 2017)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 24 Oct 2017 MabVax Therapeutics files for patent protection with the USPTO for its HuMab-Tn fully-human monoclonal antibodies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top